Two studies have previously investigated the differences in the toxicities of PD1 and PD‐L1 inhibitors.24, 25 Khunger et al reported a higher incidence of immune‐related pneumonitis with use of PD‐1 inhibitors compared with PD‐L1 inhibitors in patients with nonsmall cell lung cancer.24 The summary of incidence of all‐grade and high‐grade pneumonitis was also reported in Table S8 of our study. The gene discussed is PDCD1; the disease is pneumonitis.